Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Companyâ€™s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight, among others.

Employees

2,700

Sector

Medical Equipment, Supplies & Distribution

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-02-06	5.120 $	+0.39%	976,916
26-02-05	5.100 $	-3.77%	1,236,490
26-02-04	5.300 $	-0.75%	1,025,441
26-02-03	5.340 $	-2.38%	1,021,470
26-02-02	5.470 $	-2.67%	794,497

Delayed Quote Nasdaq, February 06, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

5.120USD

Average target price

8.120USD

Spread / Average Target

+58.59%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
5.120 ^USD	+0.39%		-8.90%	-16.75%

Jan. 27	Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data	CI
Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM

Capitalization	477M 404M 370M 351M 651M 43.24B 681M 4.3B 1.7B 20.81B 1.79B 1.75B 74.93B	P/E ratio 2025 *	-1.26x	P/E ratio 2026 *	-7.59x
Enterprise value	457M 387M 355M 336M 624M 41.4B 652M 4.12B 1.63B 19.93B 1.71B 1.68B 71.75B	EV / Sales 2025 *	0.56x	EV / Sales 2026 *	0.52x
Free-Float	97.98%	Yield 2025 *	-	Yield 2026 *	-

Jan. 27	Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data	CI
Jan. 14	Myriad Genetics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 05:15 PM
Jan. 12	Myriad Genetics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 and 2026	CI
Jan. 12	Myriad Genetics announces select preliminary fourth quarter and full year 2025 financial results and introduces full year 2026 financial guidance	RE
Dec. 19	Indian Equities Rebound on Friday as Rupee Stability Lifts Sentiment	MT
Dec. 19	Zydus Lifesciences Signs Pact to Launch Cancer-Risk Assessment Diagnostic Tests in India	MT
Dec. 18	Zydus Lifesciences signs agreement with Myriad Genetics for cancer-risk tests in India	RE
Dec. 18	Zydus Lifesciences Limited Signs an Exclusive Agreement with Myriad Genetics	CI
Nov. 26	Sector Update: Health Care Stocks Edge Higher Premarket Wednesday	MT
Nov. 25	Myriad Genetics Collaborates With Clairity, MagView to Roll Out AI Platform for Breast Cancer Risk Assessment	MT
Nov. 25	Clairity, Myriad Genetics, Inc. and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health	CI
Nov. 10	Myriad Genetics Expands Cancer Test With Additional Actionable Genes From NCCN Guidelines	MT
Nov. 10	Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk®? Hereditary Cancer Test to Support Evolving Clinical Needs	CI

Nov. 04	UBS Adjusts Myriad Genetics Price Target to $8 From $6, Maintains Neutral Rating	MT
25-08-07	UBS Adjusts Price Target on Myriad Genetics to $6 From $7, Maintains Neutral Rating	MT
25-08-06	Top Midday Gainers	MT
25-05-21	Myriad Genetics Shares Fall After Downgrade From Scotiabank	MT
25-05-21	Scotiabank Downgrades Myriad Genetics to Sector Perform From Sector Outperform, Adjusts Price Target to $6 From $20	MT

Myriad Genetics, Inc. Stock

Equities

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Valuation: Myriad Genetics, Inc.

Chart: Myriad Genetics, Inc.

Latest news: Myriad Genetics, Inc.

Last Transcript: Myriad Genetics, Inc.

Analysts' recommendations: Myriad Genetics, Inc.

Press Releases: Myriad Genetics, Inc.

News in other languages: Myriad Genetics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Myriad Genetics, Inc.

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Jan. 27	Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data	GL
Jan. 12	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance	GL
Jan. 05	Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference	GL
Dec. 09	Myriad Genetics to Present 8 Abstracts about MRD and Other Studies at 2025 San Antonio Breast Cancer Symposium	GL
Nov. 25	Clairity, Myriad Genetics, and MagView Launch the First Integrated AI and Genetic Risk Platform for Personalized Breast Health	GL

24-05-08	Eurobio Scientific : accord avec Myriad Genetics
22-08-31	Un nuovo studio pubblicato sulla rivista Clinical Cancer Research mette in evidenza l’impiego del test EndoPredict per indicare quale trattamento adottare in pazienti con tumore al seno in premenopausa
22-08-31	Une nouvelle étude publiée dans le Clinical Cancer Research Journal met en avant l’utilisation du test EndoPredict pour éclairer les décisions thérapeutiques chez les patientes préménopausées atteintes d’un cancer du sein
22-08-31	Nuevo estudio publicado en Clinical Cancer Research Journal destaca el uso de la prueba EndoPredict para informar el tratamiento en pacientes premenopáusicas con cáncer de mama
22-08-31	Neue Studie, im Clinical Cancer Research Journal veröffentlicht, unterstreicht die Bedeutung des EndoPredict-Tests zur Information über die Behandlung von prämenopausalen Brustkrebs-Patientinnen

1 day	+0.39%
1 week	-8.90%
Current month	-8.90%
1 month	-21.47%
3 months	-19.12%
6 months	-9.70%
Current year	-16.75%

1 week	5.01	5.7
1 month	5.01	7.15
Current year	5.01	7.15
1 year	3.76	15.47
3 years	3.76	29.3
5 years	3.76	36.95
10 years	3.76	50.44

Manager	Title	Age	Since
Samraat Raha CEO	Chief Executive Officer	54	2025-04-29
Benjamin Wheeler DFI	Director of Finance/CFO	43	2025-08-15
Dale Muzzey CTO	Chief Tech/Sci/R&D Officer	46	2014-03-31

Director	Title	Age	Since
S. Phanstiel CHM	Chairman	67	2020-03-22
Paul Bisaro BRD	Director/Board Member	65	2022-10-30
Lee Newcomer BRD	Director/Board Member	73	2019-09-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MYRIAD GENETICS, INC.	+0.39%	-8.90%	-59.78%	-73.07%	477M
BIOMÉRIEUX	-2.77%	-3.07%	-16.99%	-2.59%	13.22B
GUARDANT HEALTH, INC.	+3.55%	-10.69%	+120.98%	+244.55%	13.12B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.53%	+0.41%	-9.35%	-13.55%	6.13B
CARIS LIFE SCIENCES, INC.	+3.53%	-5.01%	-	-	6.21B
DIASORIN S.P.A.	-1.47%	+1.80%	-28.07%	-39.72%	4.68B
LANTHEUS HOLDINGS, INC.	+0.05%	-3.03%	-28.61%	+8.11%	4.3B
AUTOBIO DIAGNOSTICS CO., LTD.	-0.82%	-0.57%	-9.84%	-47.85%	3B
ANDON HEALTH CO., LTD.	+1.42%	+1.08%	+5.21%	-19.11%	2.54B
Average	+0.37%	-2.55%	-3.31%	+7.10%	5.97B
Weighted average by Cap.	+0.43%	-3.70%	+21.19%	+57.15%

	2025 *	2026 *
Net sales	823M 696M 638M 605M 1.12B 74.53B 1.17B 7.42B 2.94B 35.88B 3.09B 3.02B 129B	868M 735M 673M 638M 1.18B 78.64B 1.24B 7.83B 3.1B 37.86B 3.26B 3.19B 136B
Net income	-379M -321M -294M -278M -517M -34.32B -540M -3.42B -1.35B -16.52B -1.42B -1.39B -59.48B	-64.81M -54.86M -50.28M -47.62M -88.43M -5.87B -92.45M -584M -231M -2.83B -243M -238M -10.18B
Net Debt	-20.25M -17.14M -15.71M -14.88M -27.63M -1.83B -28.89M -183M -72.28M -883M -75.94M -74.38M -3.18B	-21.79M -18.44M -16.9M -16.01M -29.72M -1.97B -31.08M -196M -77.76M -950M -81.7M -80.02M -3.42B